Efficacy and safety Of artemether‑lumefantrine for the treatment Of uncomplicated malaria and prevalence Of Pfk13 and Pfmdr1 polymorphisms After a decade of using artemisinin‑based Combination therapy in mainland Tanzania
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
BMC
Abstract
The World Health Organization recommends regular therapeutic efficacy studies (TES) to monitor the
performance of first and second-line anti-malarials. In 2016, efficacy and safety of artemether-lumefantrine (AL) for the
treatment of uncomplicated falciparum malaria were assessed through a TES conducted between April and October
2016 at four sentinel sites of Kibaha, Mkuzi, Mlimba, and Ujiji in Tanzania. The study also assessed molecular markers of
artemisinin and lumefantrine (partner drug) resistance.
Description
Citation
Ishengoma, D.S., Mandara, C.I., Francis, F., Talundzic, E., Lucchi, N.W., Ngasala, B., Kabanywanyi, A.M., Mahende, M.K., Kamugisha, E., Kavishe, R.A. and Mohamed, A., 2019. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malaria journal, 18(1), p.88.